Queen Margaret University logo
    • Login
    View Item 
    •   QMU Repositories
    • eResearch
    • School of Health Sciences
    • The Institute for Global Health and Development
    • View Item
    •   QMU Repositories
    • eResearch
    • School of Health Sciences
    • The Institute for Global Health and Development
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Cost of oncology drugs in the Middle-Eastern country of Lebanon: An update (2014-2016)

    Date
    2018-12
    Author
    Elias, Fadia
    Bou-Orm, Ibrahim
    Adib, Salim M.
    Gebran, Selim
    Gebran, Anthony
    Ammar, Walid
    Metadata
    Show full item record
    Citation
    Elias, F., Bou-Orm, I.R., Adib, S.M., Gebran, S., Gebran, A. and Ammar, W. (2018) ‘Cost of oncology drugs in the middle-eastern country of Lebanon: an update(2014-2016)’, Journal of Global Oncology, (4), pp. 1–7. Available at: https://doi.org/10.1200/JGO.17.00179.
    Abstract
    Purpose This study aims to evaluate trends in the increasing costs of oncology drugs procured by the Lebanese Ministry of Public Health (MOPH) between 2014 and 2016 and to assess the impact of the introduction in mid-2015 of new immunotherapy drugs for the treatment of lung cancer on the overall and specific costs of that treatment. Methods A secondary analysis of data from the MOPH Cancer Drug Scientific Committee data base was conducted using a total of 18,133 cancer files between 2014 and 2016. Results Over the 3-year period, about $140 million (USD) was spent on cancer drugs by the MOPH free cancer drug dispensing program. The expenditures increased by 27% after immunotherapy was phased in. The average cost of drugs per patient per year measured across all cancer types increased from $7,000 in 2014 to $8,400 in 2016. Trastuzumab, approved for treating human epidermal growth factor receptor 2–positive breast cancer ranked first in total expenditures for 2014-2015. By 2016, two new immunotherapy drugs had topped the list: pembrolizumab ranked first and nivolumab ranked third, representing 64% of the total cost of lung cancer treatment and approximately 19% of the total yearly budget; beneficiaries represented only 3% of all patients. Conclusion This update documents the increasing financial impact of newer cancer drugs on the procurement process in the middle-income country of Lebanon. The trend is aligned with the financial burden of cancer drugs worldwide, which calls for a collaborative global response to this crisis.
    URI
    https://eresearch.qmu.ac.uk/handle/20.500.12289/10233
    Official URL
    https://doi.org/10.1200/JGO.17.00179
    Collections
    • The Institute for Global Health and Development

    Queen Margaret University: Research Repositories
    Accessibility Statement | Repository Policies | Contact Us | Send Feedback | HTML Sitemap

     

    Browse

    All QMU RepositoriesCommunities & CollectionsBy YearBy PersonBy TitleBy QMU AuthorBy Research CentreThis CollectionBy YearBy PersonBy TitleBy QMU AuthorBy Research Centre

    My Account

    LoginRegister

    Queen Margaret University: Research Repositories
    Accessibility Statement | Repository Policies | Contact Us | Send Feedback | HTML Sitemap